Full Press Release Details
Inc. Signs R&D Collaboration Letter of Intent Agreement With Aeras Global TB
2010 (GlobeNewswire) --
Wash., Feb. 1, 2010 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV) announced
that it has signed a Letter of Intent (LOI) with Aeras Global TB Vaccine
Foundation to enter into an R&D collaboration effort. The overall goal of
this collaboration will be to evaluate the efficacy of TAP in concert with novel
vaccine vectors encoding TB immunogens under development at Aeras with the aim
of advancing suitable candidates to clinical development. Aeras will conduct all
pre-clinical development studies.
one of the foremost non-profit Product Development Partnerships, is dedicated to
the development of effective TB vaccine regimens that will prevent tuberculosis
in all age groups and will be affordable, available and adopted
has extensive experience and associated intellectual property related to the use
of TAP1 and TAP2 expressing vectors for the treatment of cancer and also as
molecular adjuvants for enhancing Class I presentation of vaccine
Corin, President of TapImmune, stated, "We are proud to team with Aeras in the
search for the next generation of vaccines to eliminate the scourge of
tuberculosis from the world. We are equally proud that our technology has
been recognized as a potential meaningful contributor in that
exploring novel approaches to enhance the effectiveness of new TB vaccines,"
said Jerald C. Sadoff, MD, the President and Chief Executive Officer of the
Aeras Global TB Vaccine Foundation. "We are looking forward to evaluating
TapImmune's adjuvant technology in our next generation genetic
Aeras Global TB Vaccine Foundation
Global TB Vaccine Foundation (www.aeras.org) is a non-profit organization
working as a Product Development Partnership to develop new tuberculosis
vaccines and ensure that they are distributed to all who need them around the
world. Aeras is funded primarily by private foundations and government aid
agencies. Aeras is based in Rockville, Maryland, where it operates a
state-of-the-art manufacturing and laboratory facility.
Inc. is a biotechnology company specializing in the development of innovative
cell based immunotherapeutics and vaccines in the areas of oncology and
infectious disease. The Company's lead product candidate, the AdhTAP
vaccine, is designed to restore and augment
presentation and subsequent recognition and killing of cancer cells by the
immune system. The Company is currently planning the development AdhTAP for the
commencement of clinical manufacturing and toxicology studies. The Company is
also developing a TAP based prophylactic vaccine which initial tests indicate
may increase the efficacy of targeted prophylactic vaccines by up to 1000
vaccine, the TAP technology has the potential to significantly improve the
efficacy of current prophylactic vaccines and enhance the creation of new ones
in the fight against pandemic infectious diseases.
TapImmune Inc. logo is available at
Statement Disclaimer
release contains forward-looking information within the meaning of the Private
Securities Litigation Reform Act of 1995. Statements in this news release
concerning the Company's expectations, plans, business outlook or future
performance, and any other statements concerning assumptions made or
expectations as to any future events, conditions, performance or other matters,
are "forward-looking statements". Forward-looking statements are by their nature
subject to risks, uncertainties and other factors which could cause actual
results to differ materially from those stored in such statements. Such risks,
uncertainties and factors include, but are not limited to the risks set forth in
the Company's most recent Form 10-K and other SEC filings which are available
through EDGAR at www.sec.gov. The Company assumes no obligation to update the
forward-looking statements.